ClinicalTrials.gg
Not yet recruitingNCT07496281OPTIA-AFUpdated Mar 27, 2026

OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation

A Phase 4 interventional study of Oral anticoagulation and Single antiplatelet therapy in Atrial Fibrillation (AF), Coronary Artery Disease and Drug-eluting Stent, sponsored by Ewha Womans University Mokdong Hospital. Not yet recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Ewha Womans University Mokdong Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Atrial Fibrillation with a site in Korea, Republic of — 61 open to participants now, 69 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.

Planned enrollment
139th of 144
2 · median 300
Started
2027
with 1 other
Phase 4
22 of 209
9 open now
Primary completion
2032-02
later than 67 of 68 live
Registered
190th of 209
by date
Lead sponsor
8 of 209
Ewha Womans University Mokdong Hospital

Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 139th largest by planned enrollment of the 144 interventional ones that give a count, is one of 2 that started in 2027, is one of 22 in phase 4, reaches primary completion later than 67 of the 68 other live ones, and was the 190th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

61 of the 209 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Atrial Fibrillation with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The OPTIA-AF trial is a prospective, multicenter randomized controlled trial designed to evaluate a rhythm-guided antithrombotic strategy in patients with atrial fibrillation (AF) who maintain durable sinus rhythm after catheter ablation and have a history of prior drug-eluting stent (DES) implantation. Current guidelines generally recommend long-term oral anticoagulation (OAC) in patients with AF, even after successful ablation, while antiplatelet therapy remains essential for prevention of coronary ischemic events following percutaneous coronary intervention.

OPTIA-AF tests whether discontinuation of non-vitamin K antagonist oral anticoagulant (NOAC) therapy with transition to single antiplatelet therapy (SAPT) is non-inferior to continued NOAC therapy in patients who maintain sinus rhythm for at least 12 months after AF ablation. Participants will be randomized in a 1:1 ratio to either continued NOAC therapy or NOAC discontinuation with SAPT.

The primary endpoint is a 24-month composite net clinical outcome including ischemic stroke, systemic embolism, myocardial infarction, definite or probable stent thrombosis, cardiovascular death, and major bleeding.

Read the detailed description

Atrial fibrillation (AF) and coronary artery disease frequently coexist, creating a complex clinical scenario in which patients require antithrombotic therapy for prevention of both thromboembolic and coronary ischemic events. Current guideline-directed management generally recommends long-term oral anticoagulation in patients with AF based on stroke risk stratification, while antiplatelet therapy remains central for prevention of stent-related ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation.

Catheter ablation has become an established rhythm-control strategy for AF, and a substantial proportion of patients achieve durable maintenance of sinus rhythm after the procedure. Emerging evidence suggests that sustained sinus rhythm following successful ablation may reduce AF-related thromboembolic risk by decreasing atrial arrhythmia burden and atrial stasis. However, the optimal long-term antithrombotic strategy in patients who maintain stable sinus rhythm after ablation and have a prior history of DES implantation remains uncertain.

The OPTIA-AF trial (Optimal Post-ablation Therapy for Ischemic and Arrhythmic Risk in Atrial Fibrillation) is designed to evaluate whether a rhythm-guided strategy of discontinuing oral anticoagulation with transition to single antiplatelet therapy is non-inferior to continued NOAC therapy in patients with durable sinus rhythm after AF ablation.

This prospective, multicenter, open-label randomized controlled trial will enroll approximately 1,000 patients with nonvalvular AF who have maintained sinus rhythm for at least 12 months following catheter ablation and are at least 12 months removed from DES implantation. Eligible participants will be randomized in a 1:1 ratio to either continued NOAC therapy or NOAC discontinuation with transition to single antiplatelet therapy (SAPT). Structured rhythm surveillance including electrocardiography and ambulatory rhythm monitoring will be performed during follow-up.

Participants will be followed for 24 months. The primary endpoint is a composite net clinical outcome including ischemic stroke, systemic embolism, myocardial infarction, definite or probable stent thrombosis, cardiovascular death, and major bleeding. Secondary outcomes include AF recurrence, AF burden, arrhythmia-related hospitalization, repeat catheter ablation, and individual components of the primary composite endpoint.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Coronary Artery Disease
  • Drug-eluting Stent

Keywords

  • Atrial fibrillation ablation
  • Antithrombotic therapy
  • Oral anticoagulation
  • Non-vitamin K antagonist oral anticoagulant
  • Single antiplatelet therapy
  • Drug-eluting stent
  • Rhythm-guided strategy
  • Catheter ablation
  • Randomized controlled trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following criteria:

    • Age ≥18 years.
    • Documented history of atrial fibrillation (paroxysmal or persistent).
    • Successful catheter ablation for atrial fibrillation performed within the previous 3-6 months.
    • Maintenance of sinus rhythm after ablation, confirmed by follow-up electrocardiography or rhythm monitoring.
    • History of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation.
    • Completion of the recommended duration of dual antiplatelet therapy (DAPT) following PCI.
    • Currently receiving oral anticoagulation therapy with a non-vitamin K antagonist oral anticoagulant (NOAC).
    • Clinically stable and considered eligible for long-term antithrombotic therapy adjustment by the treating physician.
    • Ability to understand the study procedures and provide written .

Exclusion criteria

  • Participants will be excluded if any of the following criteria are present:

    • Recurrent atrial fibrillation documented after the index ablation procedure requiring repeat ablation or antiarrhythmic escalation.
    • Presence of mechanical heart valve or moderate-to-severe mitral stenosis.
    • Indication for long-term anticoagulation independent of atrial fibrillation (e.g., venous thromboembolism, mechanical valve).
    • Recent acute coronary syndrome or PCI within the past 3 months.
    • Planned coronary revascularization or cardiac surgery.
    • History of intracranial hemorrhage or other major bleeding that contraindicates antithrombotic therapy.
    • Severe renal dysfunction (e.g., estimated \<30 mL/min/1.73 m²).
    • Severe hepatic dysfunction associated with coagulopathy.
    • Known or to aspirin or NOAC therapy.
    • Pregnancy or breastfeeding.
    • less than 1 year due to non-cardiovascular comorbidities.
    • Participation in another interventional clinical trial that may interfere with the study outcomes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (estimated)

Study arms

  • Experimental
    Rhythm-guided antithrombotic strategy

    Discontinuation of oral anticoagulation with continuation of single antiplatelet therapy after atrial fibrillation ablation.

    Drug: Single antiplatelet therapy

  • Active comparator
    Continuous oral anticoagulation

    Continuation of oral anticoagulation therapy after atrial fibrillation ablation in patients with prior drug-eluting stent implantation.

    Drug: Oral anticoagulation

Interventions

  • DrugOral anticoagulation

    Non-vitamin K antagonist oral anticoagulant therapy used for stroke prevention in atrial fibrillation.

  • DrugSingle antiplatelet therapy

    Single antiplatelet therapy such as aspirin or a P2Y12 inhibitor.

06

What researchers measure

Primary outcomes

  1. Number of participants with net clinical outcome events

    Composite of ischemic stroke, systemic embolism, myocardial infarction, definite or probable stent thrombosis, cardiovascular death, and major bleeding, assessed as time-to-first event.

    Time frame: From randomization up to 24 months

Secondary outcomes

  1. Number of participants with ischemic stroke

    Occurrence of ischemic stroke, defined according to standard clinical criteria.

    Time frame: From randomization up to 24 months

  2. Number of participants with systemic embolism

    Occurrence of systemic embolism confirmed by imaging or clinical diagnosis.

    Time frame: From randomization up to 24 months

  3. Number of participants with myocardial infarction

    Occurrence of myocardial infarction defined according to universal definition criteria.

    Time frame: From randomization up to 24 months

  4. Number of participants with definite or probable stent thrombosis

    Occurrence of definite or probable stent thrombosis according to ARC criteria.

    Time frame: From randomization up to 24 months

  5. Number of participants with cardiovascular death

    Death resulting from cardiovascular causes.

    Time frame: From randomization up to 24 months

  6. Number of participants with major bleeding

    Major bleeding defined according to ISTH criteria.

    Time frame: From randomization up to 24 months

  7. Number of participants with clinically relevant non-major bleeding

    Clinically relevant non-major bleeding defined according to ISTH criteria.

    Time frame: From randomization up to 24 months

  8. Number of participants with atrial fibrillation recurrence

    Any documented atrial fibrillation episode lasting more than 30 seconds.

    Time frame: From randomization up to 24 months

  9. Atrial fibrillation burden (percentage of time in AF)

    Percentage of time in atrial fibrillation measured by ambulatory monitoring or wearable monitoring.

    Time frame: From randomization up to 24 months

  10. Number of participants with arrhythmia-related hospitalization

    Hospitalization related to atrial arrhythmia.

    Time frame: From randomization up to 24 months

  11. Number of participants undergoing repeat catheter ablation

    Repeat catheter ablation for recurrent atrial arrhythmia.

    Time frame: From randomization up to 24 months

Other outcomes

  1. Number of participants with any adverse events

    Occurrence of adverse events including bleeding, drug-related adverse events, and serious adverse events.

    Time frame: From randomization up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) will be made available upon reasonable request to the corresponding author after publication of the primary results.

Supporting information: Study protocol

Time frame: Data will be available beginning 6 months after publication of the primary results and will remain available for at least 5 years.

Access criteria: Access will be provided to qualified researchers for scientific purposes following approval of a research proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Feb 2032, 59 months later.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 59 months is above that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2026
First posted
Mar 27, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Feb 28, 2032
CompletionEst.
Mar 1, 2035
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07496281
Lead sponsor
Ewha Womans University Mokdong Hospital
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Feb 28, 2032 (estimated)
Completion
Mar 1, 2035 (estimated)
Last update
Mar 27, 2026

Study contacts

Yeji Kim, MD, PhD
Contact
lexie6169@gmail.com
+82-10-8680-9542

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion